5-Day Mammography Course for Technologists

Sep 23rd, 2013Sep 27th, 2013

Waukesha, WI

US

http://www.mtmi.net/courses/MM.php

Phone:800-765-6864

This comprehensive course uses lecture sessions, radiographs, and hands-on training sessions with live models to enhance your skills and understanding of the mammography process.

(A,B) Images from an initial ultrasound examination showed no identifiable lesions and received a consensus ultrasound category of US-1. Nearly the entire liver is visualized, with minimal shadowing (“s”, A and B), and the examination received consensus result of VIS-A. The AFP level was 7.1 ng/mL on assessment six months before the ultrasound, 9.1 ng/mL on assessment three months before examination, and 14.2 ng/mL on assessment on exam day. The AFP result was thus assessed as positive based on a progressive increase on two consecutive tests. The atient was considered to have negative surveillance result according to LI-RADS Ultrasound Surveillance v2017, but positive surveillance result according to LI-RADS Ultrasound Surveillance v2024. (C-D) Axial arterial-phase (C) and portal-venous phase (D) T1-weighted images from subsequent gadoxetic acid-enhanced MRI show a 2-cm arterial-phase hyperenhancing observation (arrow, C) with portal-venous washout (arrow, D) in segment 7. This observation was classified on MRI as LR-5, thus meeting the present study’s reference standard for diagnosis of HCC. The mass is located in the periphery of the liver, an anatomic area where ultrasound visualization can be challenging due to shadowing.

LI-RADS ultrasound surveillance version 2024 improves HCC detection

January 22, 2025

Deep learning helps find, segment lung tumors on CT imaging

January 22, 2025

EVT promising in patients with extracranial ICA occlusions

January 21, 2025

Images depict a 49-year-old female participant with cryptogenic cirrhosis who presented with a 3.2-cm liver lesion. This biopsy-confirmed hepatocellular carcinoma (HCC) with an initial categorization of Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) at CT was upgraded to LR-5 (definitely HCC) at contrast-enhanced ultrasound (CEUS). (A) Precontrast CT images in the liver show vague hypoattenuation in the medial left hepatic lobe (arrows). (B) Arterial phase images demonstrate no definite arterial phase hyperenhancement (arrows). (C) Washout and an enhancing capsule (arrows) on a late-phase image resulted in an LR-4 categorization. (D) B-mode ultrasound shows a round hypoechoic nodule (arrows). (E) An early-phase CEUS image shows clear arterial-phase hyperenhancement (arrows); (F) No washout at one minute (arrows), and (G) late, mild washout at four minutes (arrows) resulted in a CEUS LR-5 categorization.

CEUS resolves indeterminate CT, MRI liver observations

January 21, 2025

LI-RADS ultrasound surveillance version 2024 improves HCC detection

By Amerigo Allegretto

The 2024 version of the LI-RADS Ultrasound Surveillance system improves detection of hepatocellular carcinoma (HCC) over earlier iterations.

January 22, 2025

(A,B) Images from an initial ultrasound examination showed no identifiable lesions and received a consensus ultrasound category of US-1. Nearly the entire liver is visualized, with minimal shadowing (“s”, A and B), and the examination received consensus result of VIS-A. The AFP level was 7.1 ng/mL on assessment six months before the ultrasound, 9.1 ng/mL on assessment three months before examination, and 14.2 ng/mL on assessment on exam day. The AFP result was thus assessed as positive based on a progressive increase on two consecutive tests. The atient was considered to have negative surveillance result according to LI-RADS Ultrasound Surveillance v2017, but positive surveillance result according to LI-RADS Ultrasound Surveillance v2024. (C-D) Axial arterial-phase (C) and portal-venous phase (D) T1-weighted images from subsequent gadoxetic acid-enhanced MRI show a 2-cm arterial-phase hyperenhancing observation (arrow, C) with portal-venous washout (arrow, D) in segment 7. This observation was classified on MRI as LR-5, thus meeting the present study’s reference standard for diagnosis of HCC. The mass is located in the periphery of the liver, an anatomic area where ultrasound visualization can be challenging due to shadowing.

Deep learning helps find, segment lung tumors on CT imaging

By Kate Madden Yee

Using a deep-learning model with lung CT imaging shows promise for identifying and segmenting tumors, researchers have reported.

January 22, 2025

EVT promising in patients with extracranial ICA occlusions

Endovascular thrombectomy (EVT) and best medical treatment are both effective and safe options for patients with acute extracranial internal carotid artery occlusions.

January 21, 2025

CEUS resolves indeterminate CT, MRI liver observations

By Amerigo Allegretto

Contrast-enhanced ultrasound (CEUS) can resolve some high-risk indeterminate liver observations initially seen on CT or MRI.

January 21, 2025

Images depict a 49-year-old female participant with cryptogenic cirrhosis who presented with a 3.2-cm liver lesion. This biopsy-confirmed hepatocellular carcinoma (HCC) with an initial categorization of Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) at CT was upgraded to LR-5 (definitely HCC) at contrast-enhanced ultrasound (CEUS). (A) Precontrast CT images in the liver show vague hypoattenuation in the medial left hepatic lobe (arrows). (B) Arterial phase images demonstrate no definite arterial phase hyperenhancement (arrows). (C) Washout and an enhancing capsule (arrows) on a late-phase image resulted in an LR-4 categorization. (D) B-mode ultrasound shows a round hypoechoic nodule (arrows). (E) An early-phase CEUS image shows clear arterial-phase hyperenhancement (arrows); (F) No washout at one minute (arrows), and (G) late, mild washout at four minutes (arrows) resulted in a CEUS LR-5 categorization.

PET/CT can rule out CAV in heart transplant patients

Cardiac PET/CT scans can effectively rule out moderate to severe cardiac allograft vasculopathy (CAV) in heart transplant patients.

January 17, 2025

Machine learning can predict immunotherapy response in NSCLC patients

By Kate Madden Yee

Machine learning (ML) can help clinicians predict immunotherapy response in patients with inoperable non-small cell lung cancer (NSCLC).

January 17, 2025

Current topics in mammography

By Sandy Coffta

Sandy Coffta of Healthcare Administrative Partners discusses changes in reporting and reimbursement for mammography exams.

January 17, 2025

Coffta Sandy Thumbnail

Surgeon General's alcohol advisory puts patient counseling at the fore

By Amerigo Allegretto

Patient communication and education may be key for radiologists in the wake of the Surgeon General’s advisory on alcohol-related cancer risk.

January 17, 2025

Wine Red Glass 400

FAPI-PET shows promise for imaging gastric cancers

Gallium-68 fibroblast activation protein inhibitor (FAPI) PET/CT is a promising new method for imaging gastric cancer.

January 16, 2025

Fapi Pet Gastric Cancer Thumbnail

CEM has slightly higher mean glandular dose than DBT, mammography

By Amerigo Allegretto

Contrast-enhanced mammography (CEM) has a slightly higher mean glandular dose than other breast imaging modalities.

January 16, 2025

Contrast Injector

ACS: Cancer mortality continues to drop

By Kate Madden Yee

Cancer mortality rates continue to drop -- although incidence of the disease is rising in women, according to an annual study released by the ACS.

January 16, 2025

Cancer Cell Target2

POCUS useful for diagnosis of retained conception tissue

By Amerigo Allegretto

Point-of-care ultrasound (POCUS) can be a useful tool for diagnosing the presence of retained conception tissue.

January 15, 2025

Ultrasound Portable

Page 1 of 111